RxDoctor Payments Data

Nicole Boyd

Family · Mount Vernon, ILNPI 1710439112

Payments from drug & device makers

$4,229in general payments, 2019–2025

Across 259 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$896
  • Otsuka America Pharmaceutical, Inc.$410
  • E.r. Squibb & Sons, L.L.C.$237
  • Lundbeck LLC$221
  • Axsome Therapeutics, Inc.$175
  • plus $584 from 8 others

What the payments were for

  • Food & beverage$4,214100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,229 in reported general payments places this provider in the 90th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$14,375
Medicare patients
25
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole17$37,732
VraylarCariprazine Hcl14$22,491
Alprazolam84$1,380
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine27$813
Bupropion XlBupropion Hcl25$693
Methylphenidate Hcl12$520
Clonazepam47$430
Escitalopram Oxalate26$427
Lorazepam46$366
Aripiprazole12$313
Duloxetine Hcl11$239
Sertraline Hcl25$234
Trazodone Hcl36$230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$410$37,73217 claims
AbbVieVraylar$1,706$22,49114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,941 family providers in Illinois.

Other family in Mount Vernon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →